Senticell

USAPhiladelphiaBiotech & PharmaSeed
Visit website →

Overview

Where Senticell is now

Senticell announced a funding round of $7M on 1 September 2026.

Observed Described in the funding announcement as "biotechnology company developing a new class of liquid biopsy built on red blood cell (RBC)-bound nucleic acids". Source

Latest round
Seed
Amount
$7M
Announced
1 September 2026
Headquarters
Philadelphia, USA
Sector
Biotech & Pharma
Investors
Not stated
Also participating
Not stated
Relevant leadership
CEO Neha Shah

Current direction Inferred

What this company is working on

ProductResearch and development

Read from the company's own description of what the funding supports.

What happens next

What this raise plausibly creates

AfterRaise inferenceInferred

Likely next Moves

  • Product launches and new tiers
  • Product leadership hiring
  • Research programme expansion
  • Scientific team growth

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Licensing and BD partnerships
  • Product leadership
  • Design partners

Based on the Biotech & Pharma sector, a Seed round and the priorities the company itself set out. Not a statement of fact.

Medium momentum3 connected signals
  • 1 September 2026$7M Seed announced
  • 1 September 2026Stated priority: product
  • 1 September 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Momentum Inferred

AfterRaise Score

58
Steady growth
1 funding signal in the last 90 days
Funding recency
40/40
announced within the last 30 days
Round scale
8/25
round size relative to the market
Funding stage
10/20
Seed
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Growth timeline

What has happened so far

  • 1 September 2026
    $7M Seed
    Investors not stated in the announcement.

Observed The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

Moves

Published by the company

Share a Move

No company-published Moves yet

AfterRaise has the funding facts for Senticell from public sources. What it does not have is what the company is doing next, in the company's own words. That part only they can write.

Work here? Publish the first Move

Opportunities

Work this company has opened

No open Opportunities listed

Jobs, projects, partnerships and advisory needs appear here once the company has claimed its room and published them.

Work here? Open the first one

Open to

Who may approach Senticell

Not yet specified

Senticell has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Work here?

Own your growth story.

This room belongs to Senticell. Claim it to tell people where you are going, confirm or correct what AfterRaise noticed, publish Moves, ask the network, control who can contact you, and share your growth story. Everything you publish is reviewed before it appears.

What we do not have yet: the roles and projects you have open. Claiming the room is how you fill those in.

Also moving

Other Biotech & Pharma companies

See the sector